Mitchell P Levesque

List of Publications by Year
in descending order

134 papers	9,086 citations	61984 43 h-index	49909 87 g-index
144 all docs	144 docs citations	144 times ranked	15821 citing authors

#	Article	IF	Citations
1	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017, 547, 453-457.	27.8	1,194
2	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013, 494, 251-255.	27.8	665
3	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 144-153.	30.7	564
4	Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, 2018, 174, 843-855.e19.	28.9	514
5	CyTOF workflow: Differential discovery in high-throughput high-dimensional cytometry datasets. F1000Research, 2017, 6, 748.	1.6	312
6	Whole-Genome Analysis of the SHORT-ROOT Developmental Pathway in Arabidopsis. PLoS Biology, 2006, 4, e143.	5.6	283
7	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature Communications, 2015, 6, 6051.	12.8	281
8	CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Research, 2017, 6, 748.	1.6	244
9	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Research, 2018, 78, 1308-1320.	0.9	238
10	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
11	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell, 2016, 29, 270-284.	16.8	198
12	Identification of bacteria-derived HLA-bound peptides in melanoma. Nature, 2021, 592, 138-143.	27.8	187
13	IL-4 abrogates T _H 17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2163-2168.	7.1	151
14	Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1Î±-Dependent Phenotype Switching. Journal of Investigative Dermatology, 2013, 133, 2436-2443.	0.7	127
15	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell, 2018, 34, 69-84.e14.	16.8	123
16	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5â^'/â^' mice. Nature Communications, 2019, 10, 1492.	12.8	114
17	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. Cancer Immunology Research, 2019, 7, 77-85.	3.4	114
18	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 2017, 116, 1141-1147.	6.4	112

#	Article	IF	Citations
19	Small molecule promotes Î²-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology, 2018, 14, 94-101.	8.0	105
20	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	12.8	102
21	Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 1289-1297.	7.0	101
22	Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Science Immunology, 2022, 7, eabk1692.	11.9	100
23	Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Scientific Reports, 2016, 6, 29914.	3.3	99
24	The mitogen-activated protein kinase pathway in melanoma part I â€“ Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer, 2017, 73, 85-92.	2.8	96
25	Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. PLoS Genetics, 2015, 11, e1004877.	3.5	85
26	Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell, 2021, 39, 1135-1149.e8.	16.8	83
27	Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nature Cancer, 2021, 2, 1387-1405.	13.2	83
28	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 2015, 16, 42.	8.8	76
29	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clinical Cancer Research, 2019, 25, 6852-6867.	7.0	74
30	Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget, 2016, 7, 77163-77174.	1.8	73
31	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell, 2021, 39, 288-293.	16.8	71
32	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	7.0	70
33	MAPK pathway in melanoma part IIâ€”secondary and adaptive resistance mechanisms to BRAF inhibition. European Journal of Cancer, 2017, 73, 93-101.	2.8	69
34	Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Science Advances, 2018, 4, eaat4758.	10.3	67
35	The ALPK1/TIFA/NF-ÎºB axis links a bacterial carcinogen to R-loop-induced replication stress. Nature Communications, 2020, 11, 5117.	12.8	67
36	The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nature Communications, 2017, 8, 1988.	12.8	64

#	Article	IF	Citations
37	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 2017, 9, 1011-1029.	6.9	63
38	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nature Medicine, 2020, 26, 1865-1877.	30.7	62
39	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports, 2015, 11, 1458-1473.	6.4	55
40	Hedgehog signaling in basal cell carcinoma. Journal of Dermatological Science, 2015, 78, 95-100.	1.9	55
41	Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology, 2018, 8, 178.	2.8	53
42	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Clinical Cancer Research, 2016, 22, 2020-2031.	7.0	51
43	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. Cancer Research, 2020, 80, 2983-2995.	0.9	51
44	Bioinformatics for precision oncology. Briefings in Bioinformatics, 2019, 20, 778-788.	6.5	49
45	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications, 2021, 12, 1434.	12.8	46
46	Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Research, 2019, 79, 2684-2696.	0.9	45
47	MITF reprograms the extracellular matrix and focal adhesion in melanoma. ELife, 2021, 10, .	6.0	45
48	Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation. Cell Stem Cell, 2019, 24, 637-653.e9.	11.1	44
49	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
50	Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget, 2016, 7, 83554-83569.	1.8	44
51	SMAD signaling promotes melanoma metastasis independently of phenotype switching. Journal of Clinical Investigation, 2019, 129, 2702-2716.	8.2	41
52	Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations. Cancer Research, 2015, 75, 4817-4829.	0.9	40
53	Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. Journal of Clinical Investigation, 2018, 128, 5531-5548.	8.2	40
54	Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Medical Weekly, 2015, 145, w14183.	1.6	38

#	Article	IF	Citations
55	Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Developmental Cell, 2021, 56, 2808-2825.e10.	7.0	37
56	SCIM: universal single-cell matching with unpaired feature sets. Bioinformatics, 2020, 36, i919-i927.	4.1	37
57	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
58	A new liveâ€cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology, 2015, 24, 377-380.	2.9	31
59	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics, 2015, 14, 2132-2142.	4.1	31
60	Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. Journal of Experimental Medicine, 2021, 218, .	8.5	31
61	PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget, 2016, 7, 75551-75560.	1.8	28
62	Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 2013, 5, 169-182.	2.0	27
63	Proteomic identification of a marker signature for <scp>MAPK</scp> i resistance in melanoma. EMBO Journal, 2019, 38, e95874.	7.8	26
64	Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. Nature Communications, 2020, 11, 4306.	12.8	26
65	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. Bioinformatics, 2018, 34, 107-108.	4.1	25
66	A Comparative Study of Real-Time RT-PCRâ€“Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. Journal of Molecular Diagnostics, 2021, 23, 796-804.	2.8	24
67	A genomeâ€wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS â€mutant melanoma. Pigment Cell and Melanoma Research, 2020, 33, 334-344.	3.3	23
68	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. Journal of Investigative Dermatology, 2020, 140, 2242-2252.e7.	0.7	23
69	Temporal activation of WNT/Î²-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene, 2020, 39, 4132-4154.	5.9	23
70	A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. Cell Reports, 2016, 15, 1884-1892.	6.4	21
71	Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. Journal of Immunotherapy, 2019, 42, 89-93.	2.4	21
72	Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVIDâ€19 patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 595-608.	5.7	21

#	Article	IF	Citations
73	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	1.8	21
74	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 2017, 27, 358-368.	1.2	20
75	Prolonged Unfrozen Storage and Repeated Freeze-Thawing of SARS-CoV-2 Patient Samples Have Minor Effects on SARS-CoV-2 Detectability by RT-PCR. Journal of Molecular Diagnostics, 2021, 23, 691-697.	2.8	19
76	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 2021, 13, 2931.	3.7	19
77	Systems biology. Current Biology, 2004, 14, R179-R180.	3.9	18
78	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making, 2018, 18, 89.	3.0	18
79	Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARÎ³ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. Cancer Research, 2018, 78, 6447-6461.	0.9	18
80	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. Clinical Proteomics, 2018, 15, 13.	2.1	17
81	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflammatory Intestinal Diseases, 2020, 5, 109-116.	1.9	17
82	Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer and Metastasis Reviews, 2017, 36, 7-21.	5.9	16
83	The NLRP1 Inflammasome Pathway Is Silenced in Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2019, 139, 1788-1797.e6.	0.7	16
84	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	8.2	16
85	Microgreens: Functional Food with Antiproliferative Cancer Properties Influenced by Light. Foods, 2021, 10, 1690.	4.3	16
86	MEK inhibition and immune responses in advanced melanoma. OncoImmunology, 2017, 6, e1335843.	4.6	15
87	Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. Nature Communications, 2021, 12, 5056.	12.8	15
88	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. Laboratory Investigation, 2021, 101, 1561-1570.	3.7	15
89	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, .	8.2	15
90	The Role of Extracellular Vesicles in Melanoma Progression. Cancers, 2022, 14, 3086.	3.7	15

#	Article	IF	Citations
91	IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Science Immunology, 2021, 6, eabg9012.	11.9	14
92	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. Frontiers in Immunology, 2021, 12, 793992.	4.8	14
93	VLA-4 mediated adhesion of melanoma cells on the bloodâ€“brain barrier is the critical cue for melanoma cell intercalation and barrier disruption. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1995-2010.	4.3	13
94	Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma. Journal of Investigative Dermatology, 2020, 140, 878-890.e5.	0.7	13
95	The role of cyclin D1 and Kiâ€67 in the development and prognostication of thin melanoma. Histopathology, 2020, 77, 460-470.	2.9	13
96	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. Molecular Cancer Research, 2020, 18, 1560-1573.	3.4	13
97	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. Journal of Clinical Oncology, 2016, 34, 9549-9549.	1.6	12
98	An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies. Frontiers in Cell and Developmental Biology, 2022, 10, 872688.	3.7	12
99	Melanoma's next top model, it is in the air. Experimental Dermatology, 2015, 24, 659-660.	2.9	11
100	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. European Journal of Cancer, 2021, 156, 149-163.	2.8	11
101	Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. Current Opinion in Oncology, 2016, 28, 172-179.	2.4	10
102	HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients. Journal of Investigative Dermatology, 2017, 137, 2443-2444.	0.7	10
103	Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor. Clinical Cancer Research, 2022, 28, 770-780.	7.0	10
104	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers, 2019, 11, 1329.	3.7	9
105	Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. , 2022, 10, e004268.		8
106	Whoâ€™s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. Cancers, 2021, 13, 2725.	3.7	7
107	Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden. Genes, 2021, 12, 974.	2.4	7
108	Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. Cancer Research, 2021, 81, 6044-6057.	0.9	7

#	Article	IF	Citations
109	A DNA replication-independent function of pre-replication complex genes during cell invasion in C. elegans. PLoS Biology, 2022, 20, e3001317.	5.6	7
110	NRAS^{Q61K} melanoma tumor formation is reduced by p38â€MAPK14 activation in zebrafish models and NRASâ€mutated human melanoma cells. Pigment Cell and Melanoma Research, 2021, 34, 150-162.	3.3	6
111	Mycobacterial infection aggravates Helicobacter pylori-induced gastric preneoplastic pathology by redirection of de novo induced Treg cells. Cell Reports, 2022, 38, 110359.	6.4	6
112	Novel Blood Vascular Endothelial Subtype-Specific Markers in Human Skin Unearthed by Single-Cell Transcriptomic Profiling. Cells, 2022, 11, 1111.	4.1	6
113	Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. Biology Open, 2018, 7, .	1.2	5
114	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Research, 2020, 30, 552-561.	1.2	5
115	A prognostic gene-signature based identification of high-risk thin melanomas.. Journal of Clinical Oncology, 2018, 36, e21575-e21575.	1.6	5
116	STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1171-1182.e10.	0.7	5
117	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
118	Coexpression of SOX10/CD271 (p75^{NTR}) and Î²-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. Dermatopathology (Basel, Switzerland), 2014, 1, 35-46.	1.5	3
119	Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-coding RNA, 2021, 7, 5.	2.6	3
120	The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, 3026-3026.	1.6	3
121	Defining the molecular landscape of cancer-associated stroma in cutaneous squamous cell carcinoma. Journal of Investigative Dermatology, 2022, , .	0.7	3
122	Lipoconstruct surface topography grating size influences vascularization onset in the dorsal skinfold chamber model. Acta Biomaterialia, 2020, 106, 136-144.	8.3	2
123	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. Journal of Clinical Oncology, 2016, 34, 9514-9514.	1.6	2
124	Advances in the drug management of basal cell carcinoma. Expert Opinion on Pharmacotherapy, 2022, 23, 573-582.	1.8	2
125	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. Frontiers in Oncology, 2022, 12, 830627.	2.8	2
126	Perturbing resistance: a network perspective. Pigment Cell and Melanoma Research, 2016, 29, 5-7.	3.3	1

#	Article	IF	Citations
127	Multi-Dimensional Biomarkers for the Personalized Treatment of Melanoma. , 2021, , 361-364.		1
128	Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.. Journal of Clinical Oncology, 2021, 39, e14532-e14532.	1.6	1
129	Collection and preprocessing of fine needle aspirate patient samples for single cell profiling and data analysis. STAR Protocols, 2021, 2, 100581.	1.2	1
130	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.. Journal of Clinical Oncology, 2019, 37, 9575-9575.	1.6	1
131	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.. Journal of Clinical Oncology, 2018, 36, 9579-9579.	1.6	1
132	To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 2014, 134, 1200-1201.	0.7	0
133	Abstract 2222: The molecular landscape of acral lentiginous melanoma in Mexican patients. , 2021, , .		0
134	568â€…Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment. , 2021, 9, A597-A597.		0